Literature DB >> 2642490

No evidence for a defect in growth hormone binding to liver membranes in thalassemia major.

M C Postel-Vinay1, R Girot, J Leger, J F Hocquette, P McKelvie, A Amar-Costesec, R Rappaport.   

Abstract

To test the hypothesis of a defect in GH-receptor interaction, which could explain the growth failure of thalassemic children, the binding of [125I]human (h) GH to membrane fractions prepared from liver biopsies was studied. Small amounts of liver were obtained from 6 girls and 11 boys with homozygous beta-thalassemia, aged 3-15 yr, all prepubertal, at the time of splenectomy. Specific binding of [125I]hGH ranged from 0.37-5.11% of the added radioactivity/100 micrograms liver membrane protein, with variations in both receptor number and binding affinity. This 14-fold variation in hGH binding to liver membranes of thalassemic children was comparable to that in membrane fractions of livers obtained from normal donors at the time of liver transplant. The binding of insulin to liver membranes from the thalassemic patients ranged from 9.8-17.9% of the added radioactivity/100 micrograms membrane protein and from 2.8-15.0%/100 micrograms membrane protein in the normal donors. Insulin and GH binding to liver membranes did not vary in a consistent way. A 3-fold difference was found in 5'-nucleotidase activity of the membrane fractions. Histological hepatic modifications were assessed with respect to siderosis and fibrosis. No correlation was found between these parameters and GH binding. These results suggest that possible membrane alterations are not the only reason for the variations in hGH binding. All patients had retarded growth, and all but 2 had low plasma insulin-like growth factor I levels. No relationship was found between the level of GH binding to liver membranes and the growth failure. Thus, a defect in GH binding to liver membranes is probably not the cause of the growth retardation of thalassemic children.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2642490     DOI: 10.1210/jcem-68-1-94

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  Endocrine complications of thalassemia.

Authors:  D Tiosano; Z Hochberg
Journal:  J Endocrinol Invest       Date:  2001-10       Impact factor: 4.256

2.  Osteoporosis and beta-thalassemia major: role of the IGF-I/IGFBP-III axis.

Authors:  A Lasco; N Morabito; A Gaudio; A Crisafulli; A Meo; G Denuzzo; N Frisina
Journal:  J Endocrinol Invest       Date:  2002-04       Impact factor: 4.256

Review 3.  Growth and endocrine function in thalassemia major in childhood and adolescence.

Authors:  M Delvecchio; L Cavallo
Journal:  J Endocrinol Invest       Date:  2010-01       Impact factor: 4.256

4.  Evaluation of hypothalamic-pituitary function in patients with thalassemia major.

Authors:  L Danesi; M Scacchi; M De Martin; A Dubini; P Massaro; A T Majolo; F Cavagnini; E E Polli
Journal:  J Endocrinol Invest       Date:  1992-03       Impact factor: 4.256

Review 5.  Growth of children with beta-thalassemia major.

Authors:  Louis Ck Low
Journal:  Indian J Pediatr       Date:  2005-02       Impact factor: 1.967

6.  Relationship of endocrinopathy to iron chelation status in young patients with thalassaemia major.

Authors:  R G Grundy; K A Woods; M O Savage; J P Evans
Journal:  Arch Dis Child       Date:  1994-08       Impact factor: 3.791

7.  Circadian growth hormone secretion in short multitransfused prepubertal children with thalassaemia major.

Authors:  G Katzos; F Harsoulis; M Papadopoulou; M Athanasiou; K Sava
Journal:  Eur J Pediatr       Date:  1995-06       Impact factor: 3.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.